These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321 [TBL] [Abstract][Full Text] [Related]
7. Estrogen/Progesterone Receptor Loss, CTNNB1 and KRAS Mutations Are Associated With Local Recurrence or Distant Metastasis in Low-Grade Endometrial Endometrioid Carcinoma. Chibbar R; Foerstner S; Suresh J; Chibbar R; Piche A; Kundapur D; Kanthan R; Kundapur V; Lee CH; Agrawal A; Lai R Appl Immunohistochem Mol Morphol; 2023 Mar; 31(3):181-188. PubMed ID: 36695555 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic Evaluation and Molecular Profiling of Recurrent Stage IA Endometrial Endometrioid Carcinoma: A Case-control Study. Sharma AE; Moran A; Somasegar S; Steinhardt G; Chapel DB; Lastra RR; Lee NK; Ritterhouse LL; Bennett JA Int J Gynecol Pathol; 2023 Jan; 42(1):26-34. PubMed ID: 35125405 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. Liu Y; Patel L; Mills GB; Lu KH; Sood AK; Ding L; Kucherlapati R; Mardis ER; Levine DA; Shmulevich I; Broaddus RR; Zhang W J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214561 [TBL] [Abstract][Full Text] [Related]
10. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Kurnit KC; Kim GN; Fellman BM; Urbauer DL; Mills GB; Zhang W; Broaddus RR Mod Pathol; 2017 Jul; 30(7):1032-1041. PubMed ID: 28281553 [TBL] [Abstract][Full Text] [Related]
11. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252 [TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001 [TBL] [Abstract][Full Text] [Related]
13. Corded and Hyalinized and Spindled Endometrioid Endometrial Carcinoma: A Clinicopathologic and Molecular Analysis of 9 Tumors Based on the TCGA Classifier. Safdar NS; Thompson EF; Gilks CB; Isacson C; Bennett JA; Clarke B; Young RH; Oliva E Am J Surg Pathol; 2021 Aug; 45(8):1038-1046. PubMed ID: 34115671 [TBL] [Abstract][Full Text] [Related]
14. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Alvarez T; Miller E; Duska L; Oliva E Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825 [TBL] [Abstract][Full Text] [Related]
15. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675 [TBL] [Abstract][Full Text] [Related]
16. FIGO Grade 3 Endometrioid Adenocarcinomas With Diffusely Aberrant β-Catenin Expression: An Aggressive Subset Resembling Cutaneous Pilomatrix Carcinomas. Weisman P; Park KJ; Xu J Int J Gynecol Pathol; 2022 Mar; 41(2):126-131. PubMed ID: 33811207 [TBL] [Abstract][Full Text] [Related]
17. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features. Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522 [TBL] [Abstract][Full Text] [Related]
18. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the Uterine Corpus are Characterized by CTNNB1 Mutations and Can Show Adverse Clinical Outcomes. Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971 [TBL] [Abstract][Full Text] [Related]
19. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment. Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108 [TBL] [Abstract][Full Text] [Related]
20. Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas. Kurihara S; Oda Y; Ohishi Y; Kaneki E; Kobayashi H; Wake N; Tsuneyoshi M Mod Pathol; 2010 Feb; 23(2):225-34. PubMed ID: 19898427 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]